Nymoen HM, Zhao Z, Horndalsveen H, Bjaanæs MM, Grønberg BH, Halvorsen T, Madebo T, Aanerud M, Koivunen J, Oselin K, Cicenas S, Helbekkmo N, Ahvonen J, Silvoniemi M, Alver TN, Dalen T, Öjlert ÅK, Farooqi SJ, Helland Å, Haakensen VD (2026)
Gut microbiota alterations in patients with non-small-cell lung cancer undergoing chemoradiotherapy
Mol Oncol (in press)
DOI 10.1002/1878-0261.70326, PubMed 42703809

Horndalsveen H, Haakensen VD, Madebo T, Grønberg BH, Halvorsen TO, Bjaanæs MM, Danielsen BK, Børve M, Kokkvoll S, Boda TSD, Öjlert ÅK, Helland Å (2026)
ctDNA-Based MRD Detection in Stage III NSCLC Treated With Chemoradiotherapy and Durvalumab
J Thorac Oncol, 103992 (in press)
DOI 10.1016/j.jtho.2026.103992, PubMed 42336205

Thunold S, Hernes E, Gyland Mikalsen LT, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Helland Å, Malinen E, Haakensen VD (2026)
Dual-time-point [¹⁸F]FDG-PET/CT as a prognostic biomarker in patients with pleural mesothelioma undergoing immunotherapy
EJNMMI Res, 16 (1)
DOI 10.1186/s13550-026-01469-x, PubMed 42322509